Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas

Cancer Treatment Reviews

Volumn 41, Issue 8, 2015, Pages 680-689

  Perez Callejo D ^a   Gonzalez Rincon J ^a   Sanchez A ^a   Provencio, M ^a   Sanchez Beato M ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Apoptosis; CD20; Monoclonal antibodies; Non Hodgkin Lymphomas; Rituximab

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAS ANTIGEN; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RITUXIMAB; TOSITUMOMAB; VELTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; B CELL NONHODGKIN LYMPHOMA; BINDING AFFINITY; CALCIUM TRANSPORT; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DOWN REGULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MEMBRANE BIOLOGY; NONHODGKIN LYMPHOMA; PROTEIN EXPRESSION; REVIEW; THERAPY RESISTANCE; TROGOCYTOSIS; DRUG EFFECTS; DRUG RESISTANCE; DRUG THERAPY; EXPERIMENTAL THERAPY; IMMUNOLOGY; LYMPHOMA, B-CELL; PROCEDURES; TRENDS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; HUMANS; LYMPHOMA, B-CELL; THERAPIES, INVESTIGATIONAL;

EID: 84941022593     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.05.007     Document Type: Review

References (123)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Méndez M., Provencio M. Rituximab: pharmacology, clinical indications and health benefits. Rituximab: pharmacology, clinical indications and health effects 2013, 1-30. Nova Science Publishers, New York, NY, USA. G.V. Lake-Bakaar (Ed.).
3. Witzens-Harig M., Foá R., Di Rocco A., van Hazel G., Chamone D.F.A., Rowe J.M., et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol 2014.
4. Deans J.P., Li H., Polyak M.J. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002, 107(2):176-182.
5. McLaughlin P., Grillo-López A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16(8):2825-2833.
6. Berinstein N.L., Grillo-López A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998, 9(9):995-1001.
7. Pfreundschuh M., Held G., Zeynalova S., Zwick C., Haenel M., LorenzTruemper L., et al. Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: results from the SEXIE-R-CHOP-14 trial of the DSHNHL. J Clin Oncol 2014, 32:5s. [suppl; abstr 8501].
8. Korfel A., Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013, 9(6):317-327.
9. Pels H., Schulz H., Manzke O., Hom E., Thall A., Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002, 59(3):213-216.
10. Maximiano Alonso C., Sánchez Ruiz A.C., Cantos Sánchez de Ibargüen B., Méndez García M., Ronco I.S., Provencio Pulla M. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. Clin Transl Oncol 2010, 12(10):701-703.
11. Marcus R., Imrie K., Solal-Celigny P., Catalano J.V., Dmoszynska A., Raposo J.C., et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008, 26(28):4579-4586.
12. Salles G., Seymour J.F., Offner F., López-Guillermo A., Belada D., Xerri L., et al. Rituximab maintenance for 2years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011, 377(9759):42-51.
13. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(4):235-242.
14. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174.
15. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54(9):2793-2806.
16. Li H., Ayer L.M., Polyak M.J., Mutch C.M., Petrie R.J., Gauthier L., et al. The CD20 Calcium Channel Is Localized to Microvilli and Constitutively Associated with Membrane Rafts antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem 2004, 279(19):19893-19901.
17. Petrie R.J., Deans J.P. Colocalization of the B-cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol 2002, 169(6):2886-2891.
18. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007, 26(25):3629-3636.
19. Li H., Ayer L.M., Lytton J., Deans J.P. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003, 278(43):42427-42434.
20. van Meerten T., van Rijn R.S., Hol S., Hagenbeek A., Ebeling S.B. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006, 12(13):4027-4035.
21. Davis T.A., Czerwinski D.K., Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999, 5(3):611-615.
22. Li Y., Williams M.E., Cousar J.B., Pawluczkowycz A.W., Lindorfer M.A., Taylor R.P. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 2007, 179(6):4263-4271.
23. Kamburova E.G., Koenen H.J.M.P., Joosten I., Hilbrands L.B LBCD19 is a useful B-cell marker after treatment with rituximab: comment on the article by Jones et al. Arthritis Rheum 2013, 65(4):1130-1131.
24. Terui Y., Mishima Y., Sugimura N., Kojima K., Sakurai T., Mishima Y., et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in Non-Hodgkin's Lymphoma. Clin Cancer Res 2009, 15(7):2523-2530.
25. Mishima Y., Terui Y., Takeuchi K., Matsumoto-Mishima Y., Matsusaka S., Utsubo-Kuniyoshi R., et al. The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer J 2011, 1(4):e15.
26. Johnson N.A., Leach S., Woolcock B., deLeeuw R.J., Bashashati A., Sehn L.H., et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 2009, 94(3):423-427.
27. Hiraga J., Tomita A., Sugimoto T., Shimada K., Ito M., Nakamura S., et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009, 113(20):4885-4893.
28. Beers S.A., French R.R., Chan H.T.C., Lim S.H., Jarrett T.C., Vidal R.M., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010, 115(25):5191-5201.
29. Czuczman M.S., Olejniczak S., Gowda A., Kotowski A., Binder A., Kaur H., et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008, 14(5):1561-1570.
30. Bonavida B. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol 2014, 41(5):667-677.
31. Nimmerjhan F., Ravetch J.V. Fcγ receptors: old friends and new family members. Immunity 2006, 24:19-28.
32. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6(4):443-446.
33. Uchida J., Hamaguchi Y., Oliver J.A., Ravetch J.V., Poe J.C., Haas K.M., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004, 199(12):1659-1669.
34. Minard-Colin V., Xiu Y., Poe J.C., Horikawa M., Magro C.M., Hamaguchi Y., et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008, 112(4):1205-1213.
35. Khan K.D., Emmanouilides C., Benson D.M., Hurst D., Garcia P., Michelson G., et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent Non-Hodgkin's Lymphoma. Clin Cancer Res 2006, 12(23):7046-7053.
36. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 2007 Oct 1, 110(7):2561-2564.
37. Persky D.O., Dornan D., Goldman B.H., Braziel R.M., Fisher R.I., LeBlanc M., et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012, 97(6):937-942.
38. Carlotti E., Palumbo G.A., Oldani E., Tibullo D., Salmoiraghi S., Rossi A., et al. FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007, 92(8):1127-1130.
39. Ghesquières H., Cartron G., Seymour J.F., Delfau-Larue M.-H., Offner F., Soubeyran P., et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 2012, 120(13):2650-2657.
40. Ahlgrimm M., Pfreundschuh M., Kreuz M., Regitz E., Preuss K.-D., Bittenbring J. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 2011, 118(17):4657-4662.
41. Fabisiewicz A., Paszkiewicz-Kozik E., Osowiecki M., Walewski J., Siedlecki J.A. FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2011, 52(8):1604-1606.
42. Danielou-Lazareth A., Henry G., Geromin D., Khaznadar Z., Briere J., Tamouza R., et al. At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. Eur J Immunol 2013, 43(5):1383-1388.
43. Galimberti S., Palumbo G.A., Caracciolo F., Benedetti E., Pelosini M., Brizzi S., et al. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. J Chemother 2007, 19(3):315-321.
44. Lin T.S., Flinn I.W., Modali R., Lehman T.A., Webb J., Waymer S., et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 2005, 105(1):289-291.
45. Treon S.P., Hansen M., Branagan A.R., Verselis S., Emmanouilides C., Kimby E., et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005, 23(3):474-481.
46. Weng W.-K., Negrin R.S., Lavori P., Horning S.J. Immunoglobulin G Fc receptor FcγRIIIA 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with Non-Hodgkin's Lymphoma. J Clin Oncol 2010, 28(2):279-284.
47. Keane C., Nourse J.P., Crooks P., Nguyen-Van D., Mutsando H., Mollee P., et al. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J 2012, 42(10):1113-1119.
48. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21(21):3940-3947.
49. Camilleri-Broët S., Mounier N., Delmer A., Brière J., Casasnovas O., Cassard L., et al. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). Leukemia 2004, 18(12):2038-2040.
50. Weng W.-K., Levy R. Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma 2009, 50(5):723-727.
51. Vega M.I., Huerta-Yepez S., Martinez-Paniagua M., Martinez-Miguel B., Hernandez-Pando R., González-Bonilla C.R., et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009, 15(21):6582-6594.
52. Chong E.A., Ahmadi T., Aqui N., Svoboda J., Nasta S.D., Mato A.R., et al. Combination of lenalidomide and rituximab overcomes rituximab-resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res 2015.
53. Zhou X., Hu W., Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008, 13(9):954-966.
54. Ollert M.W., Kadlec J.V., David K., Petrella E.C., Bredehorst R., Vogel C.W. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 1994, 153(5):2213-2221.
55. Gaetano N.D., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003, 171(3):1581-1587.
56. Dalle S., Dupire S., Brunet-Manquat S., Reslan L., Plesa A., Dumontet C. In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res 2009, 15(3):851-857.
57. Kennedy A.D., Beum P.V., Solga M.D., DiLillo D.J., Lindorfer M.A., Hess C.E., et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004, 172(5):3280-3288.
58. Racila E., Link B.K., Weng W.-K., Witzig T.E., Ansell S., Maurer M.J., et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008, 14(20):6697-6703.
59. Jin X., Ding H., Ding N., Fu Z., Song Y., Zhu J. Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Hematol Oncol 2012, 16(5):51.
60. Manches O., Lui G., Chaperot L., Gressin R., Molens J.-P., Jacob M.-C., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101(3):949-954.
61. Bannerji R., Kitada S., Flinn I.W., Pearson M., Young D., Reed J.C., et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003, 21(8):1466-1471.
62. Weng W.-K., Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001, 98(5):1352-1357.
63. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001, 98(12):3383-3389.
64. Macor P., Tripodo C., Zorzet S., Piovan E., Bossi F., Marzari R., et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007, 67(21):10556-10563.
65. Di Gaetano N., Xiao Y., Erba E., Bassan R., Rambaldi A., Golay J., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001, 114(4):800-809.
66. Hu W., Ferris S.P., Tweten R.K., Wu G., Radaeva S., Gao B., et al. Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat Med 2008, 14(1):98-103.
67. Bellosillo B., Villamor N., López-Guillermo A., Marcé S., Esteve J., Campo E., et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001, 98(9):2771-2777.
68. Wojciechowski W., Li H., Marshall S., Dell'Agnola C., Espinoza-Delgado I. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J Immunol 2005, 174(12):7859-7868.
69. Mishima Y., Terui Y., Mishima Y., Kuniyoshi R., Matsusaka S., Mikuniya M., et al. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRIIIa polymorphism. Int Immunol 2012, 24(8):477-483.
70. Van der Kolk L.E., Evers L.M., Omene C., Lens S.M.A., Lederman S., van Lier R., et al. CD20-induced B-cell death can bypass mitochondria and caspase activation. Leukemia 2002, 16(9):1735-1744.
71. Chan H.T.C., Hughes D., French R.R., Tutt A.L., Walshe C.A., Teeling J.L., et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res 2003, 63(17):5480-5489.
72. Daniels I., Turzanski J., Haynes A.P. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab. Br J Haematol 2008, 142(3):394-403.
73. Daniels I., Abulayha A., Haynes A.P. Hydroxyurea potentiates the caspase-independent killing of B-cell lines by rituximab and GA101. Oncol Res 2012, 20(12):545-555.
74. Unruh T.L., Li H., Mutch C.M., Shariat N., Grigoriou L., Sanyal R., et al. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology 2005, 116(2):223-232.
75. Winiarska M., Bil J., Wilczek E., Wilczynski G.M., Lekka M., Engelberts P.J., et al. Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. PLoS Med 2008, 5(3):e64.
76. Vega M.I., Huerta-Yepez S., Jazirehi A.R., Garban H., Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005, 24(55):8114-8127.
77. Vega M.I., Jazirehi A.R., Huerta-Yepez S., Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in ramos Non-Hodgkin's lymphoma cell line via inhibition of NF-κB activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005, 175(4):2174-2183.
78. Wieder T., Essmann F., Prokop A., Schmelz K., Schulze-Osthoff K., Beyaert R., et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001, 97(5):1378-1387.
79. Stel A.J., ten Cate B., Jacobs S., Kok J.W., Spierings D.C.J., Dondorff M., et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B-cells to Fas-induced apoptosis. J Immunol 2007, 178(4):2287-2295.
80. Eeva J., Nuutinen U., Ropponen A., Mättö M., Eray M., Pellinen R., et al. The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells. Apoptosis 2009, 14(5):687-698.
81. Bremer E., ten Cate B., Samplonius D.F., Mueller N., Wajant H., Stel A.J., et al. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res 2008, 68(2):597-604.
82. Olejniczak S.H., Hernandez-Ilizaliturri F.J., Clements J.L., Czuczman M.S. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008, 14(5):1550-1560.
83. Pro B., Leber B., Smith M., Fayad L., Romaguera J., Hagemeister F., et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008, 143(3):355-360.
84. Staudt L.M. Oncogenic activation of NF-κB. Cold Spring Harb Perspect Biol 2010, 2(6):a000109.
85. Jazirehi A.R., Huerta-Yepez S., Cheng G., Bonavida B. Rituximab (Chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in Non-Hodgkin's Lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65(1):264-276.
86. Vega M.I., Martínez-Paniagua M., Huerta-Yepez S., González-Bonilla C., Uematsu N., Bonavida B. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 MAb: implication in chemosensitization. Int J Oncol 2009, 35(6):1289-1296.
87. Vega M.I., Martinez-Paniagua M., Jazirehi A.R., Huerta-Yepez S., Umezawa K., Martinez-Maza O., et al. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008, 49(10):1982-1994.
88. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26(22):3279-3290.
89. Alas S., Emmanouilides C., Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell Non-Hodgkin's Lymphoma to apoptosis. Clin Cancer Res 2001, 7(3):709-723.
90. Jazirehi A.R., Gan X.-H., Vos S.D., Emmanouilides C., Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B-cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003, 2(11):1183-1193.
91. Vega M.I., Huerta-Yepaz S., Garban H., Jazirehi A., Emmanouilides C., Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004, 23(20):3530-3540.
92. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002, 99(4):1314-1319.
93. Alas S., Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant Non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003, 9(1):316-326.
94. Jazirehi A.R., Vega M.I., Chatterjee D., Goodglick L., Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of Non-Hodgkin's Lymphoma B-cells by rituximab. Cancer Res 2004, 64(19):7117-7126.
95. Jazirehi A.R., Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2004, 3(1):71-84.
96. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30(2):193-204.
97. Uddin S., Hussain A.R., Siraj A.K., Manogaran P.S., Al-Jomah N.A., Moorji A., et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108(13):4178-4186.
98. Hasselblom S., Hansson U., Olsson M., Torén L., Bergström A., Nilsson-Ehle H., et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 2010, 149(4):560-568.
99. Suzuki E., Umezawa K., Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007, 26(42):6184-6193.
100. Furman R.R., Sharman J.P., Coutre S.E., Cheson B.D., Pagel J.M., Hillmen P., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370(11):997-1007.
101. Gopal A.K., Kahl B.S., de Vos S., Wagner-Johnston N.D., Schuster S.J., Jurczak W.J., et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014, 370(11):1008-1018.
102. Kahl B.S., Spurgeon S.E., Furman R.R., Flinn I.W., Coutre S.E., Brown J.R., et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014, 123(22):3398-3405.
103. Barnes J.A., Jacobsen E., Feng Y., Freedman A., Hochberg E.P., LaCasce A.S., et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2013, 98(4):615-619.
104. Hess G., Herbrecht R., Romaguera J., Verhoef G., Crump M., Gisselbrecht C., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27(23):3822-3829.
105. Ansell S.M., Tang H., Kurtin P.J., Koenig P.A., Inwards D.J., Shah K., et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a multi-center Phase 2 study. Lancet Oncol 2011, 12(4):361-368.
106. Nishida M., Uematsu N., Kobayashi H., Matsunaga Y., Ishida S., Takata M., et al. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol 2011, 38(2):335-344.
107. Cheson B.D. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010, 28(21):3525-3530.
108. Rafiq S., Butchar J.P., Cheney C., Mo X., Trotta R., Caligiuri M., et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 2013, 190(6):2702-2711.
109. Baig N.A., Taylor R.P., Lindorfer M.A., Church A.K., LaPlant B.R., Pettinger A.M., et al. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol 2014, 192(4):1620-1629.
110. Hagenbeek A., Gadeberg O., Johnson P., Pedersen L.M., Walewski J., Hellmann A., et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008, 111(12):5486-5495.
111. Coiffier B., Lepretre S., Pedersen L.M., Gadeberg O., Fredriksen H., van Oers M.H.J., et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008, 111(3):1094-1100.
112. Furtado M., Dyer M.J.S., Johnson R., Berrow M., Rule S. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial. Br J Haematol 2014, 165(4):575-578.
113. Coiffier B., Radford J., Bosly A., Martinelli G., Verhoef G., Barca G., et al. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol 2013, 163(3):334-342.
114. Czuczman M.S., Kahanic S., Forero A., Davis G., Munteanu M., VanDenNeste E., et al. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B-cell non-Hodgkin's lymphoma. Ann Hematol 2015.
115. Morschhauser F., Leonard J.P., Fayad L., Coiffier B., Petillon M.-O., Coleman M., et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009, 27(20):3346-3353.
116. Negrea G.O., Elstrom R., Allen S.L., Rai K.R., Abbasi R.M., Farber C.M., et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica 2011, 96(4):567-573.
117. Morschhauser F., Marlton P., Vitolo U., Lindén O., Seymour J.F., Crump M., et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010, 21(9):1870-1876.
118. Lim S.H., Levy R. Translational medicine in action: anti-CD20 therapy in lymphoma. J Immunol 2014, 193(4):1519-1524.
119. Roghanian A., Teige I., Mårtensson L., Cox K.L., Kovacek M., Ljungars A., et al. Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer Cell 2015, 27(4):473-488.
120. Salles G.A., Morschhauser F., Solal-Céligny P., Thieblemont C., Lamy T., Tilly H., et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013, 31(23):2920-2926.
121. Morschhauser F.A., Cartron G., Thieblemont C., Solal-Céligny P., Haioun C., Bouabdallah R., et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013, 31(23):2912-2919.
122. Radford J., Davies A., Cartron G., Morschhauser F., Salles G., Marcus R., et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 2013, 122(7):1137-1143.
123. Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C.M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014, 370(12):1101-1110.